Best Practice & Research Clinical Rheumatology
Volume 20, Issue 1 , Pages 117-129 , February 2006

Acetaminophen or NSAIDs for the treatment of osteoarthritis

  • Bernard Bannwarth, MD (Professor of Therapeutics)

      Affiliations

    • Corresponding Author InformationTel.: +33 5 56 79 55 56; Fax: +33 5 56 93 04 07.

References 

  1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines . Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis and Rheumatism. 2000;43:1905–1915
  2. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidenced based approach to the management of knee osteoarthritis: report of a Task Force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Annals of the Rheumatic Diseases. 2003;62:1145–1155
  3. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Annals of the Rheumatic Diseases. 2005;64:669–681
  4. Say RE, Thomson R. The importance of patient preferences in treatment decisions–challenges for doctors. British Medical Journal. 2003;327:542–545
  5. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomized controlled trials. Annals of the Rheumatic Diseases. 2004;63:901–907
  6. Bjordal JM, Ljunggren AE, Klovning A, Slordal S. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis of randomized placebo-controlled trials. British Medical Journal. 2004;329:1317–1320
  7. Pincus T, Koch G, Lei H, et al. Patient preference for placebo, acetaminophen (paracetamol) or celecoxib efficacy studies (PACES): two randomized, double blind, placebo-controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Annals of the Rheumatic Diseases. 2004;63:931–939
  8. Miceli-Richard C, Le Bars M, Schmidely N, Dougados M. Paracetamol in osteoarthritis of the knee. Annals of the Rheumatic Diseases. 2004;63:923–930
  9. Neame R, Zhang W, Doherty M. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis. Annals of the Rheumatic Diseases. 2004;63:897–900
  10. Graham GG, Scott KF. Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11:401–413
  11. Warner TD, Vojnovic I, Giuliano F, et al. Cyclooxygenases 1, 2 and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. The Journal of Pharmacology and Experimental Therapeutics. 2004;310:642–647
  12. Bannwarth B. Gastrointestinal safety of paracetamol: is there any cause for concern?. Expert Opinion on Drug Safety. 2004;3:269–272
  13. Garcia-Rodriguez LA, Hernandez-Dias S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570–576
  14. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal anti-inflammatory drugs in an elderly population. Arthritis and Rheumatism. 2002;46:3046–3054
  15. Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious gastrointestinal bleeding: a meta-analysis based on individual patient data. British Journal of Clinical Pharmacology. 2002;54:320–326
  16. Abramson SB. Et tu, acetaminophen?. Arthritis and Rheumatism. 2002;46:2831–2835
  17. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Safety. 2005;28:227–240
  18. Ofman JJ, Maclean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. The Journal of Rheumatology. 2002;29:804–812
  19. Laine L. Gastrointestinal effects of NSAIDs and coxibs. Journal of Pain and Symptom Management. 2003;25(supplement):S32–S40
  20. Perazella MA. COX-2 selective inhibitors: analysis of the renal effect. Expert Opinion on Drug Safety. 2002;1:53–64
  21. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HGM. Effects of NSAIDs on the incidence of hospitalisation for renal dysfunction in users of ACE inhibitors. Drug Safety. 2003;26:983–989
  22. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Archives of Internal Medicine. 2005;165:490–496
  23. Bannwarth B. Do selective cyclo-oxygenase-2 inhibitors have a future?. Drug Safety. 2005;28:183–189
  24. Singh G, Miller JD, Huse DM, et al. Consequences of increased systolic pressure in patients with osteoarthritis and rheumatoid arthritis. The Journal of Rheumatology. 2003;30:714–719
  25. Egan BM. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;4:601–603
  26. Curhan GC, Willet WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Archives of Internal Medicine. 2002;162:2204–2208
  27. Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604–608
  28. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. The New England Journal of Medicine. 1994;331:1675–1679
  29. Segasothy M, Chin GL, Sia KK, et al. Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. British Journal of Rheumatology. 1995;34:162–165
  30. Courtney P, Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Annals of the Rheumatic Diseases. 2002;61:767–773
  31. Bannwarth B, Péhourcq F. Pharmacological rationale for the clinical use of paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs. 2003;63(2):5–13[special issue]
  32. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacological Reviews. 2001;53:357–379
  33. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. British Medical Journal. 2004;328:434–437
  34. Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allergie et Immunologie (Paris). 2004;36:215–218
  35. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase-2 inhibitors rofecoxib and valdecoxib. Annals of Allergy Asthma and Immunology. 2005;94:34–38
  36. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics. 2004;20:373–380
  37. Wegman A, Van der Windt D, Van Tulder M, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. The Journal of Rheumatology. 2004;31:344–354
  38. Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis and Rheumatism. 2001;44:1587–1598
  39. Fraenkel L, Bogardus ST, Concato J, Wittink DR. Treatment options in knee osteoarthritis. The patient's perspective. Archives of Internal Medicine. 2004;164:1299–1304
  40. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis and Rheumatism. 2000;43:378–385
  41. Pincus T, Swearingen C, Cummings P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. The Journal of Rheumatology. 2000;27:1020–1027
  42. Scott DL, Kingsley G. Translating research into practice: acetaminophen in osteoarthritis revisited. The Journal of Rheumatology. 2003;30:199–202
  43. March L, Irwig L, Schwarz J, et al. n Of 1 trials comparing non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. British Medical Journal. 1994;309:1041–1045
  44. Wegman ACM, Van der Windt DAWM, de Haan M, et al. Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with osteoarthritis. Annals of the Rheumatic Diseases. 2003;62:1156–1161
  45. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clinical and Experimental Rheumatology. 2001;19(supplement 25):S15–S22
  46. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet. 2004;364:665–674
  47. Mahajan A, Sharma A. COX-2 selective nonsteroidal anti-inflammatory drugs: current status. The Journal of the Association of Physicians of India. 2005;53:200–204
  48. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patient with arthritis. The New England Journal of Medicine. 2002;347:2104–2110
  49. Spiegel BMR, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal anti-inflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis and Rheumatism. 2005;53:185–197
  50. Clark DWJ, Layton D, Shakir SAW. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Safety. 2004;27:427–456
  51. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. British Medical Journal. 2005;330:440
  52. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs. Archives of Internal Medicine. 2005;165:978–984
  53. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases. A comparison. Drugs. 2000;60:555–574
  54. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. British Medical Journal. 2004;329:324–326
  55. Cooper C. Topical NSAIDs in osteoartritis. Best used for short periods during flare-ups in the disease. British Medical Journal. 2004;329:304–305
  56. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee. A randomized, double-blind, vehicle-controlled clinical trial. Archives of Internal Medicine. 2004;164:2017–2023
  57. Bagheri H, Lhiaubet V, Montastruc JL, Chouini-Lalanne N. Phorosensitivity to ketoprofen. Mechanisms and pharmacoepidemiological data. Drug Safety. 2000;22:339–349

PII: S1521-6942(05)00106-3

doi: 10.1016/j.berh.2005.09.004

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 1 , Pages 117-129 , February 2006

Article Tools